Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MYOC | Q99972 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | MAOA | P21397 | 3/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25192703 | 1.00 | MAPT (1.00) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL31233153 | 1.00 | MAPT (1.00) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL5508056 | 1.00 | MAPT (1.00) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL25219836 | 0.88 | MAOB (0.89) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL25191373 | 0.88 | MAOB (0.89) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL25195966 | 0.88 | MAOB (0.89) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL25233412 | 0.88 | MAOB (0.89) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL9318926 | 0.87 | TERT (0.82) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL8847550 | 0.87 | MAPT (0.77) | MAPTKMT2APTGS1PTGS2KDM4E | |
| SCHEMBL8847553 | 0.87 | MAPT (0.77) | MAPTKMT2APTGS1PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | claimed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | claimed |
| JP-63002925-A | — | — | None | — | — | JP | disclosed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-1254658-B1 | REMEDIES FOR THE TREATMENT OF NERVE DIORDERS | TAKARA BIO INC (JP) | 2008-09-24 | — | — | EP | disclosed |
| US-7268160-B2 | Remedies | TAKARA BIO, INC. (JP) | 2007-09-11 | — | — | US | disclosed |
| EP-1254658-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002066443-A2 | 2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-29 | — | — | WO | disclosed |
| EP-0629602-B1 | 3,4-Dihydroxychalcone derivatives | NIPPON HYPOX LAB INC (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0370461-B1 | Chalcone derivatives and process for producing the same | DAINIPPON INK & CHEMICALS (JP) | 1995-06-28 | — | — | EP | disclosed |
| EP-0629602-A1 | 3,4-Dihydroxychalcone derivatives | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-5276058-A | Antiinflammatory agents | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1994-01-04 | — | — | US | disclosed |
| US-5068364-A | Antiulcer agents, antiallergens | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0370461-A2 | Chalcone derivatives and process for producing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-05-30 | — | — | EP | disclosed |
| JP-S632925-A | C-KINASE INHIBITOR AND ANTI-TUMOR AGENT | NIPPON KAYAKU CO LTD | 1988-01-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885KMT2A 2792/4885PTGS1 522/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885KMT2A 3188/4885PTGS1 180/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885KMT2A 3188/4885PTGS1 180/4885 |
| US-20070092551-A1 | Therapeutic agent | FABP4, GPR119, IAPP | MAPT 2256/4885KMT2A 4418/4885PTGS1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.